All In Biotech

Drug Trial Radar · NCT06159504

Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania

Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania (CUTTS HepC): a Non-randomised, Quasiexperimental, Prospective Comparative Trial

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,040

Planned (sponsor's estimate)

Start

Oct 3, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Médecins du MondeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UNITAID; Burnet Institute; University of Bristol; International Network of People who Use Drugs
First posted
Dec 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania. The main questions it aims to answer are: 1. What is the feasibility of implementing a hepatitis C simplified care and same-day treatment care model in community and harm reduction settings in the three study countries? 2. Does a same-day treatment initiation model involving only POC antibody tests (with a shortened read-time) increase hepatitis C treatment uptake and SVR12 outcome (cure) among people who inject drugs compared with a simplified care model involving POC antibody followed by a confirmatory RNA test? 3. What is the comparative cost-effectiveness between a same-day antibody only hepatitis C testing and treatment model and the simplified care model (POC antibody/confirmatory RNA test) model? Participants will: * be enrolled in a new simplified model of care in each country (Arm 1). After the enrolment target is met for Arm 1 (approx. 3-9 months into implementation) new participants will be enrolled into a same-day treatment trial, using presumptive treatment after a reactive POC test result at shortened read-time (5minutes) (Arm 2) * if in Arm 1, participants will commence SOF-VEL DAA treatment after receiving an RNA test to confirm current hepatitis C infection. They will then continue along the treatment pathway, returning for RNA testing 4-16 weeks after SVR12 to determine cure. * if in Arm 2, participants will begin SOF-VEL DAA treatment on the same day as the 5 minute RDT testing. They will then continue along the treatment pathway, returning for RNA testing 4-16 weeks after SVR12 to determine cure. Researchers will compare cure and participant retention rates between the two groups.

Conditions

  • Hepatitis C
  • RDT

Interventions

  • sofosbuvir/velpatasvir (SOF/VEL)Drug

    400mg of SOF and 100mg of VEL self administered daily as a tablet.

  • Shortened read time of rapid diagnostic test for hepatitis C virus.Diagnostic test

    Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The feasibility of implementing a hepatitis C simplified care (Arm 1) and same-day treatment (Arm 2) care models in community and harm reduction settings in the three study countries.Time frame: 3 years
  2. The proportion of participants initiating hepatitis C treatment in simplified care Arm vs same-day treatment Arm.Time frame: 3 years
  3. The proportion of participants who achieve SVR following hepatitis C treatment in simplified care Arm vs same-day treatment Arm.Time frame: 3 years
  4. The comparative cost and cost-effectiveness of simplified care vs same-day treatment models of care.Time frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute for Infectious Diseases

    Yerevan, Armenia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.